dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pascual, Tomás |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Ciruelos, Eva |
dc.contributor.author | Gavilá Gregori, Joaquín |
dc.contributor.author | Espinosa Bravo, Martin |
dc.contributor.author | Arumí De Dios, Míriam |
dc.contributor.author | Bellet Ezquerra, Meritxell |
dc.contributor.author | Saura Manich, Cristina |
dc.date.accessioned | 2021-12-23T12:54:29Z |
dc.date.available | 2021-12-23T12:54:29Z |
dc.date.issued | 2021-04 |
dc.identifier.citation | Pascual T, Oliveira M, Ciruelos E, Bellet Ezquerra M, Saura C, Gavilá J, et al. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Front Oncol. 2021 Apr;11:685. |
dc.identifier.issn | 2234-943X |
dc.identifier.uri | https://hdl.handle.net/11351/6730 |
dc.description | Breast Cancer; CelTIL Score; Patritumab deruxtecan |
dc.description.abstract | Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)–positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecular biology, tumor microenvironment, and mechanisms of drug resistance in breast cancer, we designed this window-of-opportunity study with the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402).
Trial Design: Based on these data, a prospective, multicenter, single-arm, window-of-opportunity study was designed to evaluate the biological effect of patritumab deruxtecan in the treatment of naïve patients with HR-positive/HER2-negative early breast cancer whose primary tumors are ≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The primary endpoint is a CelTIL score after one single dose. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study. |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Oncology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Medicaments - Assaigs clínics |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fonc.2021.638482 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | evaluación de medicamentos |
dc.relation.publishversion | https://doi.org/10.3389/fonc.2021.638482 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pascual T] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (Instituto de Investigaciones Biomédicas August Pi i Sunyer), Barcelona, Spain. [Oliveira M, Bellet Ezquerra M, Saura C] SOLTI Innovative Cancer Research, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ciruelos E] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain. [Gavilá J] SOLTI Innovative Cancer Research, Barcelona, Spain. Medical Oncology Department, IVO—Fundación Instituto Valenciano de Oncología, Valencia, Spain. [Espinosa-Bravo M] Unitat de Cirurgia de Càncer de Mama, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Arumi de Dios M] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33968735 |
dc.identifier.wos | 000648033700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |